FDA Greenlights Whole-Room Germ-Zapping Devices
Published Date: 9/10/2026
Rule
Summary
The Food and Drug Administration (FDA) is classifying the whole room microbial reduction device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the whole room microbial reduction device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device moved to Class II rules
FDA has classified the whole room microbial reduction device as Class II (special controls). The device is subject to premarket notification under section 510(k) and must meet special controls such as non-clinical performance testing, biocompatibility testing, software verification and validation, electromagnetic and electrical safety testing, and labeling.
Creates a 510(k) predicate pathway
Because FDA granted De Novo classification, the whole room microbial reduction device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. FDA received the De Novo request on February 1, 2023, and issued the classification order on September 1, 2023.
Required safety testing and labeling rules
The rule requires specific safety and performance controls: testing for microbial log reduction, simulated worst-case and in-use performance, photobiological lamp safety, material compatibility, biocompatibility, software verification and validation, electromagnetic and electrical safety, and labeling. Labels must include warnings and instructions to ensure the device is operated in an unoccupied environment, setup and positioning instructions, and information about material compatibility.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18431, Medical Devices; Cardiovascular Devices; Classification of the Extravascular Support for an Arteriovenous Fistula for Vascular Access
The Food and Drug Administration (FDA) is classifying the extravascular support for an arteriovenous fistula for vascular access into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the extravascular support for an arteriovenous fistula for vascular access. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18432, Medical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedures
The Food and Drug Administration (FDA) is classifying the temperature regulation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the temperature regulation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18433, Medical Devices; Cardiovascular Devices; Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation Procedures
The FDA is officially classifying a new device that protects the esophagus during heart procedures as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get access to this cool innovation faster by cutting down on red tape. The new classification took effect on September 10, 2026, but has been in place since September 6, 2023, making it easier and potentially cheaper for makers to bring this device to market.
Previous / Next Documents
Previous: 2026-18423, Airworthiness Directives; International Aero Engines AG Engines; Correction
The FAA is correcting an airworthiness directive (AD) that was published in the Federal Register. That AD applies to certain International Aero Engines AG (IAE AG) Model V2522-A5, V2524-A5, V2525- D5, V2527-A5, V2527E-A5, V2527M-A5, V2528-D5, V2530-A5, V2531-E5, and V2533-A5 engines. As published, paragraph (g) of the regulatory text contains a typographical error. This document corrects that error. In all other respects, the original document remains the same.
Next: 2026-18427, Medical Devices; Radiology Devices; Classification of the Vaginal Hydrogel Packing System
The Food and Drug Administration (FDA) is classifying the vaginal hydrogel packing system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the vaginal hydrogel packing system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.